Study was funded by Sobi and Sanofi.

Publication

ISTH •
25 June, 2024 •
•

First Interim Analysis of Clinical Outcomes in Adults and Adolescents With Severe Hemophilia A Receiving Efanesoctocog Alfa Prophylaxis in XTEND-ed, a Phase 3 Long-term Extension Study

Sophie Susen, Stephanie P’ng, Toshko Lissitchkov, Davide Matino, Pratima Chowdary, Angela Weyand, Robert Klamroth, Young-Shil Park, María Teresa Álvarez Román, Liqi Feng, Helena Palmborg, Jennifer Dumont , Elena Santagostino, Lila-Sabrina Fetita, Keiji Nogami

Available materials

Oral Presentation

Publication

ISTH •
25 June, 2024 •
•

Long-term Outcomes With Efanesoctocog Alfa Prophylaxis for Previously Treated Children With Severe Hemophilia A, an Interim Analysis of the Phase 3 XTEND-ed Study

Lynn Malec, Beatrice Nolan, Anthony KC Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Available materials

Oral Presentation

Publication

ISTH •
22 June, 2024 •
•

Long-Term Joint Health Outcomes With a Recombinant Factor VIII Fc From the 48-Month Prospective, Observational A-MORE Study: Third Interim Analysis of Up to 24 Months

Jan Astermark, Johannes Oldenburg, Ruben Berrueco, Annarita Tagliaferri, Mikaela Alenäs, Markus Fusser, Stefan Lethagen

Available materials

Poster

Perioperative Management with Efanesoctocog Alfa in Adults, Adolescents, and Children with Severe Hemophilia A in the Phase 3 XTEND Clinical Program

First Interim Analysis of Clinical Outcomes in Adults and Adolescents With Severe Hemophilia A Receiving Efanesoctocog Alfa Prophylaxis in XTEND-ed, a Phase 3 Long-term Extension Study

Long-term Outcomes With Efanesoctocog Alfa Prophylaxis for Previously Treated Children With Severe Hemophilia A, an Interim Analysis of the Phase 3 XTEND-ed Study

Long-Term Joint Health Outcomes With a Recombinant Factor VIII Fc From the 48-Month Prospective, Observational A-MORE Study: Third Interim Analysis of Up to 24 Months

Joint health outcomes with efanesoctocog alfa in adults/adolescents from XTEND-1 continuing XTEND-ed

Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Observational Study of Prophylactic Efanesoctocog Alfa for Joint Health in Hemophilia A: PROTECT-ALT

Long-term observational joint health study in patients initiating efanesoctocog alfa: baseline data